Lv71
4950 积分 2024-07-26 加入
The Medicinal Chemistry of Therapeutic Oligonucleotides
27天前
已完结
Advances in oligonucleotide drug delivery
28天前
已完结
Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver
28天前
已完结
2024 FDA TIDES (Peptides and Oligonucleotides) Harvest
28天前
已完结
A renaissance in targeting the PI3K/AKT/mTOR pathway
30天前
已完结
Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation
1个月前
已完结
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
1个月前
已完结
Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises
1个月前
已完结
PROTAC targeted protein degraders: the past is prologue
1个月前
已完结
Diversified design strategies for small-molecule PROTACs: How do we select?
1个月前
已完结
皖公网安备34019202002308
